Clinical trial registry record

Treatment of Age-related Macular Degeneration Using Retinal Stem and Progenitor Cells

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Unknown.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 14, 2022.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05187104
Last registry update
September 14, 2022
Status
Unknown
Phase
Phase 1, Phase 2
Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Enrollment
20
Countries
Belarus
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NON RANDOMIZED · PARALLEL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
20
Population
ALL · 18 Years to 80 Years
Duration
2022-03-01 to 2023-12-31
Intervention
Cultured retinal stem and progenitor cells; Standard treatment according to the clinical protocols
Comparator
Patients with age-related macular degeneration receiving standard treatment
Outcomes measured
Visual acuity — 1 month; Visual acuity — 1 year; Adverse effects associated with the therapy — 1 month; Adverse effects associated with the therapy — 1 year
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON